Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M de Boer

Showing results (391-400 of 797) with videos related to

Pageof 80
Sort By:
Animal Feed Science and Technology|April 8, 2020
Evaluating the effects of storage conditions on dry matter loss and nutritional quality of grain legume fodders in West AfricaD B Akakpo, I J M de Boer, S Adjei-Nsiah, et al.
Biochemistry|November 27, 2023
Promiscuous Yet Specific: A Methionine-Aromatic Interaction Drives the Reaction Scope of the Family 1 Glycosyltransferase <i>Gm</i>UGT88E3 from SoybeanRuben M de Boer, Dan E H Hvid, Elisa Davail, et al.
The Netherlands Journal of Medicine|February 11, 2004
Chronic active Epstein-Barr virus infection in an adult with no detectable immune deficiencyM de Boer, M J T M Mol, M J J T Bogman, et al.
Journal of Occupational Rehabilitation|July 21, 2018
What Employer Actions Are Considered Most Important for the Return to Work of Employees with Cancer? A Delphi Study Among Employees and EmployersM A Greidanus, S J Tamminga, A E de Rijk, et al.
Journal of Affective Disorders|January 6, 2019
Obsessive compulsive disorder with and without hoarding symptoms: Characterizing differencesYentl E Boerema, Mijke M de Boer, Anton J L M van Balkom, et al.
Tissue Antigens|May 6, 2015
KIR3DL1 and KIR3DL2 gene copy number variation in axial spondyloarthritisS Vendelbosch, M de Boer, D van der Heijde, et al.
Anti-Cancer Drugs|December 10, 1999
Phase I and pharmacologic study of BMS-181174 given as a 6 h infusion every 4 weeks to patients with advanced solid tumorsA S Planting, J H Schellens, M E van der Burg, et al.
British Journal of Cancer|May 1, 1996
Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitorJ H Schellens, G J Creemers, J H Beijnen, et al.
Journal of Occupational Rehabilitation|November 24, 2018
Barriers to and Facilitators of Implementing Programs for Return to Work (RTW) of Cancer Survivors in Four European Countries: A Qualitative StudySietske J Tamminga, Anna M Braspenning, Anna Haste, et al.
The Science of the Total Environment|July 19, 2023
Recoupling livestock and feed production in the Netherlands to reduce environmental impactsBenjamin van Selm, Renske Hijbeek, Martin K van Ittersum, et al.
Pageof 80

Showing results (391-400 of 797) with videos related to

Sort By:
Pageof 80
Animal Feed Science and Technology|April 8, 2020
Evaluating the effects of storage conditions on dry matter loss and nutritional quality of grain legume fodders in West AfricaD B Akakpo, I J M de Boer, S Adjei-Nsiah, et al.
Biochemistry|November 27, 2023
Promiscuous Yet Specific: A Methionine-Aromatic Interaction Drives the Reaction Scope of the Family 1 Glycosyltransferase <i>Gm</i>UGT88E3 from SoybeanRuben M de Boer, Dan E H Hvid, Elisa Davail, et al.
The Netherlands Journal of Medicine|February 11, 2004
Chronic active Epstein-Barr virus infection in an adult with no detectable immune deficiencyM de Boer, M J T M Mol, M J J T Bogman, et al.
Journal of Occupational Rehabilitation|July 21, 2018
What Employer Actions Are Considered Most Important for the Return to Work of Employees with Cancer? A Delphi Study Among Employees and EmployersM A Greidanus, S J Tamminga, A E de Rijk, et al.
Journal of Affective Disorders|January 6, 2019
Obsessive compulsive disorder with and without hoarding symptoms: Characterizing differencesYentl E Boerema, Mijke M de Boer, Anton J L M van Balkom, et al.
Tissue Antigens|May 6, 2015
KIR3DL1 and KIR3DL2 gene copy number variation in axial spondyloarthritisS Vendelbosch, M de Boer, D van der Heijde, et al.
Anti-Cancer Drugs|December 10, 1999
Phase I and pharmacologic study of BMS-181174 given as a 6 h infusion every 4 weeks to patients with advanced solid tumorsA S Planting, J H Schellens, M E van der Burg, et al.
British Journal of Cancer|May 1, 1996
Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitorJ H Schellens, G J Creemers, J H Beijnen, et al.
Journal of Occupational Rehabilitation|November 24, 2018
Barriers to and Facilitators of Implementing Programs for Return to Work (RTW) of Cancer Survivors in Four European Countries: A Qualitative StudySietske J Tamminga, Anna M Braspenning, Anna Haste, et al.
The Science of the Total Environment|July 19, 2023
Recoupling livestock and feed production in the Netherlands to reduce environmental impactsBenjamin van Selm, Renske Hijbeek, Martin K van Ittersum, et al.
Pageof 80